Dr. Bruce Bode Looks Back and Forward at Automated Glucose Control Systems in Hospital Settings at ATTD20 Close Concerns and diaTribe covered Glytec co-founder Dr. Bruce Bode’s presentation ATTD 2020 (Advanced Technologies & Treatments for Diabetes) as he explored the past, present and future of automated glucose control systems in hospital settings Dr. Bruce Bode summarized decades of experience in …
Drs. Umpierrez and Cardona publish economic and clinical results of the GLUCO-CABG trial, leveraging Glytec’s Glucommander™ for personalized insulin dosing.
A study from Emory University published in the April 2017 issue of Journal of Diabetes and Its Complications (Cardona, et al. 2017) observes a near-20% reduction in perioperative complications, a 1.2-day reduction in ICU stay and a $3,654 reduction in per-patient hospitalization costs for coronary artery bypass graft (CABG) surgery. The reported outcomes, which included no severe hypoglycemia less than 40 mg/dL, were derived from an intensive glycemic control protocol supported by Glytec’s Glucommander™ for personalized insulin dosing.
Cardiovascular (CVD) patients receiving personalized insulin therapy using a software-based hyperglycemia management program had dramatically fewer hospital readmissions than those given standard care, according to two studies from Mountain States Health Alliance health care system.
The retrospective studies focused on readmission rates for three patient populations admitted for CVD indications between January and December 2015. The results showed that compared with patients treated with standard care, coronary artery bypass graft patients were readmitted 68% less often with the software program; congestive heart failure patients were readmitted 65% less often; and acute myocardial infarction patients were readmitted 36% less often, the investigators reported at the 2016 Annual Diabetes Technology Meeting.
The findings come as CMS targets cardiac procedures in both its hospital readmission reduction program and in a bundled payment model set to take effect July 1, 2017.
Glytec, which has FDA clearance for a cloud-based system to manage insulin dosing, selected MSHA as a research site for its electronic glucose management system, or eGMS. According to the studies Parsons and Mumpower presented in November at the Diabetes Technology Meeting showcase, eGMS produced sharp drops in readmission rates in 3 areas of cardiac care.
By identifying patients who needed blood glucose control treatment sooner, readmission costs were significantly reduced.
In a recent study, a health system in Tennessee with 13 hospitals started using eGMS with cardiac patients. The results were impressive. Hospital readmissions for heart attack patients were reduced by more than one third. And the readmission rate for patients with bypass surgery or congestive heart failure was reduced by about two thirds.
Two studies presented at the 16th Annual Diabetes Technology Meeting showcase readmission reductions as high as 68% with Glytec’s solution.
Two new studies presented at last week’s Diabetes Technology Meeting further validate the ability of Glytec’s eGlycemic Management System® (eGMS®) to achieve dramatic readmission reductions for patient populations at the center of new at-risk and value-based reimbursement models, including the CMS Hospital Readmission Reduction Program (HRRP) and impending bundled payment for coronary artery bypass graft surgery (CABG).
Intensive insulin therapy, with the help of a patient-specific IV insulin dosing platform, helped reduce post-cardiac surgery complications, according to a new study from Emory University.
A total of 302 patients were looked at after coronary artery bypass graft (CABG) surgery. Results demonstrated that providing more precise insulin dosing via the Glucommander IV led to improved glycemic control and a significant reduction in the rate of hypoglycemia, which is a common side effect of intensive insulin therapy in patients undergoing cardiac surgery.
Study from Emory University published in Diabetes Care leverages Glytec’s Glucommander IV platform to evaluate the optimal level of glycemic control needed to improve outcomes.
Glytec, the pioneer and leader in providing innovative glucose management software solutions central to effective diabetes management, is pleased to share the results of the GLUCO-CABG trial conducted by Emory University, which demonstrated intensive insulin therapy resulted in a reduction in post cardiac surgery complications. Hyperglycemia is common in patients undergoing cardiac surgery, reported in 60-90 percent of patients with a known history of diabetes and in more than half of patients without diabetes.
Leading industry experts present the benefits of automated glucose management for both IV and subcutaneous insulin dosing.
Glytec, the pioneer and leader in providing innovative glucose management software solutions central to effective diabetes management, today announced that several abstracts featuring the company’s eGlycemic Management System® (eGMS®) were selected as poster presentations at the American Association of Clinical Endocrinologists (AACE) 24th Annual Scientific and Clinical Congress, which took place from May 13-17th in Nashville, Tennessee.
Wide range of studies further demonstrates significant impact in the emergency department, hospital and outpatient settings.
Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, today announced that several abstracts featuring the company’s eGlycemic Management Solution® (eGMS®) have been selected as poster presentations at the International Hospital Diabetes Meeting (IHDM), taking place from May 8-9th in San Francisco. Hosted by the Diabetes Technology Society, the fifth annual IHDM conference will showcase the optimal use of future and current technologies for people with diabetes in both critical and non-critical care settings.